CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL): what the price requires

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/CRL

Headline

Field	Value
Ticker	CRL
Company	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Current price	$229.31/sh
Composition	RMS (Research Models and Services) 21% / DSA (Discovery and Safety Assessment) 60% / Manufacturing Solutions 19%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin needed	9.8%
Operating margin today	10.7%
Margin compression implied	-0.9pp
Must persist for	7.4y
Multiple paid	32x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 9.7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

How unusual the bet is: high

Reference	Value
vs own history	+0.89σ
cohort percentile (of 112 peers)	80
sustained it ~7.4 years at this level	21%
implied end-window share	0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	4.24x	3	expensive
Earnings	2.79x	3	expensive
Relative	0.46x	3	justifies
Growth	1.20x	3	expensive

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=12)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$112.94	2.03x	yes	FCF base $0.4B, growth 0% (input: historical growth), terminal g 0.5%, WACC 9.1%, 5yr projection
DCF Exit Multiple	Growth	$246.30	0.93x	yes	Exit EV/EBITDA: 25.2x / 27.2x / 29.2x (bear / base = today's held flat / bull), 5yr
Relative Valuation	Relative	$493.60	0.46x	yes	P/S fallback (negative EPS): Sector P/S 6.0x × TTM revenue — excluded from consensus
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$60.07	3.82x	yes	Reference only (book value floor): BV/sh $60.07, ROE negative
Two-Stage Excess Return	Asset	$54.06	4.24x	yes	Reference only (book value with convergence): BV/sh $60.07, ROE converges to ke
Discounted Future Market Cap	Growth	$191.22	1.20x	yes	Rev $4.0B, growth 0% (input: historical growth; tapered), Terminal P/S: 2.4x / 2.8x / 3.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair Value	Relative	$0.00	—	no	Negative/zero EPS — earnings-based value floored at $0
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$105.80	2.17x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.49B × (1−21%) / WACC 9.1% → EPV (no growth)
Residual Income	Asset	—	—	no	—
Graham Number	Asset	—	—	no	—
EV/EBITDA Relative	Relative	$167.55	1.37x	yes	EBITDA $0.42B × sector EV/EBITDA 20.0x
FCF Yield	Earnings	$82.17	2.79x	yes	FCF $391.3M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$64.43	3.56x	yes	SBC-adj FCF $0.31B (FCF $0.39B − SBC $0.08B) capitalized at Kₑ
Ben Graham Formula	Earnings	—	—	no	—
ROIC-Justified P/B	Asset	$19.83	11.56x	yes	BV $60.07 × (ROIC 3.0% / WACC 9.1%)
P/Sales Sector	Relative	$493.60	0.46x	yes	Revenue $4.03B × sector P/S 6.0x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	—	—	no	—
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$2.5b
Net debt / NOPAT (after-tax)	7.32x
Net debt / operating income (pre-tax)	5.79x
Interest coverage	3.9x
Share count CAGR (buyback)	-1.2%
Burning cash	no

Bullet Takeaways

• Charles River is the lab behind the lab: its largest segment, Discovery and Safety Assessment at roughly 60% of revenue, runs the preclinical safety testing drug developers must complete before a molecule reaches a human, which ties its fortunes to how much money flows into biopharma research.
• The defining risk is the demand cycle it serves: the company's filings note the DSA business "continued to experience lower volume driven by more cautious client spending as a result of the biopharmaceutical demand environment."
• What to watch is the turnaround under new leadership: COO Birgit Girshick became CEO on May 5, 2026 with activist Elliott on the board, a strategic review underway, and DSA bookings showing early signs of stabilizing at a 1.04x book-to-bill.

Bull Case

Start with the balance sheet, because it tells you how management is playing the hand. Charles River carries roughly $2.5 billion of net debt against a business generating around $390 million of free cash flow, and rather than retrench, it has been investing through the downturn. The clearest example is the roughly $510 million it committed to bring non-human primate supply in-house, a vertical-integration move that only makes sense if management believes the demand it serves recovers and the supply chain is worth controlling. A team that spends half a billion securing inputs during a soft patch is signaling confidence in the other side of it.

The franchise is genuinely hard to replicate. Charles River supplies the research models and runs the safety assessment work that sits at the front of every drug program, and its filings describe a portfolio that includes "specialized strains with compromised immune systems, which are in demand as early-stage tools in the drug research and development process." Drug developers do not switch preclinical providers casually, because the testing has to be consistent, validated, and regulator-trusted. That stickiness is why the DSA backlog held near $1.92 billion even through a weak demand year, and why a book-to-bill of 1.04x matters: it means more work is being booked than burned, the first sign the cycle is turning.

The catalyst for re-rating is the combination of recovery and restructuring. Management guides 2026 operating margin expansion of 120 to 150 basis points and at least $100 million of incremental cost savings, and it is doing this with a reshaped board that includes directors tied to Elliott and a new CEO who ran the operations. The bull case is that the GAAP earnings are depressed by the cycle and by one-time charges, the underlying cash generation is intact, the cost program lifts margins, and a sticky, essential franchise re-rates as biopharma spending normalizes. If DSA demand is stabilizing, as the bookings suggest, the operating leverage on the way back up is substantial.

Bear Case

The variable with the most leverage on this thesis is one Charles River does not control: how much money flows into drug development. Its DSA segment is a direct read on biopharma research budgets, and when those budgets tighten, the work dries up. The company says so plainly, attributing weakness to a DSA business that "continued to experience lower volume driven by more cautious client spending as a result of the biopharmaceutical demand environment." Biopharma R&D spending is sensitive to interest rates, to the pace of venture and IPO funding for emerging biotechs, and to large-cap pharma's own patent-cliff math. The current price does not appear to discount a scenario where that demand stays soft for longer than a year, and the 2026 guidance itself still calls for organic revenue to decline 0.5% to 1.5%.

The second risk is regulatory and specific to this business: the supply of research animals. Charles River's models depend on non-human primates, and that supply has been in turmoil since China's export ban, with the pivot to Cambodian sourcing running into a US government investigation. The company warns in its own filings that if it is unable to supply "the non-human primates in our possession to our clients because of governmental restrictions or limitations, our business may be materially adversely affected." The $510 million in-house supply deals are an attempt to control that risk, but they also concentrate exposure to a politically and ethically contested input, and they add capital outlay at a time the business is already levered.

The valuation is the hardest part for the bull to clear. The methods we use to triangulate split sharply: the relative-multiple comparison against the services sector says the price could be reasonable on revenue, but the asset-value and earnings-power methods say the price is expensive, several multiples above where book value plus profitability and capitalized current earnings land. State the requirement plainly: at today's price the market pays a multiple that implies operating profit holds near its self-funding ceiling for around six years, a pace only about 28% of comparable fast-growers sustained, and the multiple sits at the very top of the peer distribution. The balance sheet adds the amplifier. Net debt near $2.5 billion against depressed GAAP operating profit means interest coverage is thin on a trailing basis, and while the cash flow services the debt comfortably today, a longer demand downturn would test that. The bear case is a cyclical, capital-intensive services business priced for a clean and quick recovery that the demand environment has not yet delivered.

Valuation

The price is making an elevated bet, and the cleanest way to see it is the multiple the market is paying on operating profit. At today's level the implied requirement is that operating profit holds near its self-funding ceiling for roughly six years, a duration only about 28% of comparable fast-growers achieved, with the multiple sitting at the very top of the peer distribution. Treat those figures as approximate, a single solve, not a measurement. The point is that this is priced as a quality compounder, not a cyclical recovering from a trough, and the gap between those two framings is the whole debate.

The methods split in a way that captures the disagreement. The relative-multiple comparison against the contract-research and services sector lands near or even above the price on a revenue basis, because Charles River's revenue is large and the segment commands a premium multiple. But the asset-value methods, anchored on book value plus profitability, and the earnings-power methods, which capitalize current cash generation, both land well below the price. One important caveat colors the read: the trailing GAAP operating profit is depressed by the cycle and by one-time charges, so the earnings-power methods are valuing a trough, and the cash-flow methods, which see roughly $390 million of free cash flow, give a more representative picture than the headline operating margin. The spread is the market paying for a normalization the trailing numbers do not yet show.

Solvency is where the read turns cautious. Net debt near $2.5 billion is real, and against depressed trailing operating profit the coverage looks thin, though the roughly $390 million of free cash flow services the debt without strain in a normal year. The company pays no dividend and has been gently reducing its share count. The downside is bounded by an essential, sticky franchise and steady cash generation, not by net cash, of which there is none. What the valuation rests on is the recovery: the DSA backlog near $1.92 billion and a 1.04x book-to-bill say demand is firming, and the 2026 cost program is built to convert that into margin. The price is paying in advance for both to arrive on schedule.

Catalysts

The governance and leadership reset is the central catalyst. Activist Elliott took a 9.9% stake and reshaped the board with four new directors, a strategic review is underway, and COO Birgit Girshick became CEO on May 5, 2026, succeeding long-time chief James Foster. An activist-influenced board plus a new operator-CEO plus a strategic review is the setup for portfolio changes, divestitures, or sharper capital allocation, and the outcome of that review is the single biggest swing factor for how value gets unlocked.

The demand recovery is the operating catalyst. DSA net bookings improved in the fourth quarter, the segment carried a 1.04x book-to-bill and a backlog near $1.92 billion, and management framed it as "stabilization of the biopharmaceutical demand environment." At the same time, 2026 guidance still projects organic revenue to decline 0.5% to 1.5%, with operating margin expansion of 120 to 150 basis points and at least $100 million of incremental cost savings, most of the benefit weighted to the second half. Each quarter that confirms bookings firming and margins expanding validates the turnaround; a relapse in client spending would undercut it.

The supply-chain catalyst is the non-human primate situation. The $510 million committed to bring primate supply in-house is meant to insulate the business from the governmental restrictions that disrupted Cambodian sourcing, with the company expecting to internally source most of its future annual supply. Execution on that integration removes a tail risk the bear case leans on. Analyst sentiment has firmed alongside the stabilization narrative, with an average price target near $212 and recent Outperform ratings, though one major bank cut its target to $160 earlier in the year, a reminder the range of views is wide. The next earnings print is the test of whether bookings and margins are tracking the guided recovery.

Peer Cohorts (Per Segment, With Filing Citations)

RMS (Research Models and Services) / DSA (Discovery and Safety Assessment) / Manufacturing (Manufacturing Solutions) (reported)

• IQV (IQVIA HOLDINGS INC.)
• (no filing in the citation store)
• ICLR (ICON plc)
• (no filing in the citation store)
• MEDP (Medpace Holdings, Inc.)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

CRL FY2025 10-K, accession 0001100682-26-000022 · Charles River Q4 2025 results · NHP supply deals, 2025 · Charles River 2026 guidance · Charles River leadership transition, 2026 · CRL solvency, latest filings · analyst notes, 2026